Xilio Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A new dual-targeted PSMA/STEAP1 cell engager with CD3 masking and CD2 co-stimulation was announced, aiming to address tumor heterogeneity and resistance in prostate cancer. INDs for this and the claudin 18.2 program are planned for 2027. The CTLA-4 and PD-1 IL-2 programs also showed promising progress.
Fiscal Year 2025
-
Phase II data show a 40% response rate for Vilastobart plus Atezolizumab in high plasma TMB MSS CRC, with deep, durable responses and a favorable safety profile. Plasma TMB is a robust, dynamic biomarker, enabling broader patient selection and potentially guiding immunotherapy in other cancers.
-
Tumor-activated masking technology is enabling safer, more effective therapies for solid tumors, with promising early results in MSS colorectal cancer and a robust pipeline of bispecific and trispecific cell engagers. Multiple pharma collaborations and key data readouts are expected mid-year.
-
Announced three new masked T-cell engager programs for solid tumors and a major collaboration with AbbVie, including $52M upfront and up to $2.1B in milestones. Preclinical data show strong efficacy and safety for both ATACR and SEECR formats, supporting further development.
-
Corrected summary: Phase 2 data for vilastobart plus atezolizumab in heavily pretreated MSS-CRC patients show a 27% response rate without liver metastases, rapid tumor reductions, and favorable safety. No confirmed responses in liver metastases, but biomarker declines suggest delayed benefit. Expansion and higher dosing are under consideration.
Fiscal Year 2024
-
Initial phase I-C data for tumor-activated Vilastobart plus atezolizumab in advanced solid tumors, including MSS-CRC with liver metastases, show encouraging early anti-tumor activity and a differentiated safety profile, supporting ongoing phase II development.
-
The GPS platform enables tumor-selective immunotherapy activation, with XTX101 and XTX301 advancing in clinical trials for MSS CRC and solid tumors, respectively. Key data from phase II and I studies, as well as new multifunctional and cell engager platforms, are expected in Q4, supported by a strong cash position and strategic partnerships.